Serlopitant

Serlopitant

Systematic (IUPAC) name
3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(Trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)-octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one
Clinical data
Routes of administration	Oral
Identifiers
CAS Number	860642-69-9
ATC code	none
PubChem	CID 23653789
ChemSpider	24686685
UNII	277V92K32B
KEGG	D09378
ChEMBL	CHEMBL447955
Chemical data
Formula	C29H28F7NO2
Molar mass	555.527 g/mol
SMILES C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CC[C@@H]3CN(C[C@H]3[C@@H]2C4=CC=C(C=C4)F)C5=CC(=O)CC5
InChI InChI=1S/C29H28F7NO2/c1-16(19-10-20(28(31,32)33)12-21(11-19)29(34,35)36)39-26-9-4-18-14-37(23-7-8-24(38)13-23)15-25(18)27(26)17-2-5-22(30)6-3-17/h2-3,5-6,10-13,16,18,25-27H,4,7-9,14-15H2,1H3/t16-,18-,25-,26+,27+/m1/s1 Key:FLNYCRJBCNNHRH-OIYLJQICSA-N

Serlopitant (VPD-737) is a drug which acts as an NK₁ receptor antagonist. It was assessed in clinical trials for the treatment of urinary incontinence and overactive bladder, but while it was superior to placebo it provided no advantage over existing approved drugs, and was not approved for further development.^[1][2]

See also

• NK₁ receptor antagonist

References

1. Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol. 2010 Aug;184(2):616-22. doi: 10.1016/j.juro.2010.03.147 PMID 20639026
2. Payton S. Urinary incontinence: Neurokinin receptor antagonist inferior to tolterodine for OAB. Nature Reviews Urology 2010; 7:418. doi:10.1038/nrurol.2010.105